abandoned); United States provisional application serial no. 60/193,371 filed on March 31, 2000 (now abandoned); and United States provisional application no. 60/136,770 filed on May 28, 1999 (now abandoned), all of which are incorporated herein by reference in their entirety.

Please amend the paragraph beginning at page 11, line 4 as follows:

Within the context of the present invention, antibodies are understood to include monoclonal antibodies and polyclonal antibodies, antibody fragments (e.g., Fab, and F(ab')2), chimeric antibodies, bifunctional or bispecific antibodies and tetrameric antibody complexes. Antibodies are understood to be reactive against a selected antigen on the surface of a nucleated cell or erythrocyte if they bind with an appropriate affinity (association constant), e.g. greater than or equal to 10^7 M^{-1}.

Please amend the paragraph beginning at page 16, line 1 as follows:

The antibody compositions are made by combining various tetrameric antibody complexes depending on which cells one wishes to deplete. The concentration of the various tetrameric antibody complexes varies: typically antibodies to antigens expressed on nucleated cells are at 10-30µg/mL in tetrameric complexes. The composition is then diluted 1/10 into the cells so the final concentrations of each anti nucleated cell antibody in the cell suspensions is 1.0-3.0µg/mL.

Please amend lines 12-13 on page 16 as follows:

1. Add 100µL antibody composition per mL of whole peripheral blood.

Please amend line 5 on page 18 as follows:

--4. Count cells and resuspend at $1x10^8$/mL.

Please amend lines 9-10 on page 18 as follows:

8. Add a tetrameric antibody complex specific to a given antigen at a final concentration of 1.0µg/mL, the synthesis of which is described in Example 1.

Please amend the paragraph beginning at page 20, line 29 as follows:

--This example demonstrates the enrichment of breast cancer cells from whole peripheral blood using the method described in Example 2. Cells from the CAMA breast cancer cell line were seeded into samples of whole peripheral blood at a frequency of $1/10^3$, $1/10^4$ and $1/10^5$. Four tumor cell enrichment cocktails of tetrameric antibody complexes were prepared. The antibody composition of the cocktails is listed in Table 11. The results, shown in Table 12, demonstrate that the method of the invention results in greater than 2 log enrichment of tumor cells with 20-50% recovery of tumor cells. The more extensive cocktail offers a greater degree of tumor cell enrichment.--

a7

Please replace the last two rows of Table 1 on page 26 as follows:

a8

TCRαβ	WT31	BD Biosciences, San Jose, CA
TCR γδ	Immu510	IMMUNOTECH, Marseille, France

Please amend Table 2 on page 27, lines 20-22 as follows:

--γδ T Cell Enrichment

a9

Anti-

αβTCR--

Please amend Table 2 (Cont'd) on page 28, lines 3-5 as follows:

~~#~~αβ T Cell Enrichment

a10

Anti-

γδ TCR~~+~~-

Please amend Table 2 (Cont'd) on page 29, lines 21-23 as follows:

a11

~~#~~CD4+ αβT Cell Enrichment

Anti-

γδTCR~~+~~

Please amend Table 2 (Cont'd) on page 32, lines 2-4 as follows:

A12	CD8+ αβT Cell Enrichment Anti- γδTCR+

In the Figure:

Please replace Figure 1 currently of record with Figure 1 submitted herewith.

In the Claims:

Please delete claims 1-20 currently of record and add new claims 21-26 as follows:

21. (New) An antibody composition comprising:

(a) an antibody capable of binding to the antigen CD45, linked, either directly or indirectly to an antibody that binds to erythrocytes; and

A13

(b) an antibody capable of binding to the antigen CD66b, linked, either directly or indirectly to an antibody that binds to erythrocytes.

22. (New) An antibody composition according to claim 21 further comprising:

(c) an antibody capable of binding to the antigen CD36, linked, either directly or indirectly to an antibody that binds to erythrocytes.

23. (New) An antibody composition according to claim 21 further comprising:

(c) an antibody capable of binding to the antigen CD2, linked, either directly or indirectly to an antibody that binds to erythrocytes;

(d) an antibody capable of binding to the antigen CD16, linked, either directly or indirectly to an antibody that binds to erythrocytes;

(e) an antibody capable of binding to the antigen CD19, linked, either directly or indirectly to an antibody that binds to erythrocytes;

(f) an antibody capable of binding to the antigen CD36, linked, either directly or indirectly to an antibody that binds to erythrocytes; and/or